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MicroRNA miR-146a has been implicated as a negative feedback
regulator of NF-κB activation. Knockout of the miR-146a gene in
C57BL/6 mice leads to histologically and immunophenotypically
deﬁned myeloid sarcomas and some lymphomas. The sarcomas
are transplantable to immunologically compromised hosts, show-
ing that they are true malignancies. The animals also exhibit
chronic myeloproliferation in their bone marrow. Spleen and mar-
row cells show increased transcription of NF-κB–regulated genes
and tumors have higher nuclear p65. Genetic ablation of NF-κB p50
suppresses the myeloproliferation, showing that dysregulation of
NF-κB is responsible for the myeloproliferative disease.
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MicroRNAs are a group of ∼19- to 23-nucleotide long non-coding RNAs that repress target gene expression by a
combination of mRNA degradation and translation inhibition
(1). Recent studies have revealed important physiological roles
of miRNAs in many aspects of mammalian hematopoiesis and
immune cell function, and their altered expression has been
linked to pathological conditions of the immune system, such as
hematologic cancers and autoimmunity (2–4).
Chronic inﬂammation contributes to cancer initiation and
progression. Among a myriad of proposed mechanisms linking
inﬂammation to cancer, NF-κB has been identiﬁed as a key
mediator of inﬂammation-induced carcinogenesis (5). Moreover,
constitutive NF-κB activation is frequently detected in many
types of lymphoid and myeloid malignancies (6, 7). Hence, un-
derstanding how NF-κB activity is down-regulated has been
a focus of study with important advances in recent years (8). In
particular, NF-κB regulation by noncoding RNAs has recently
begun to be characterized. A few years ago, we carried out a
microarray screen to identify miRNAs induced by NF-κB acti-
vation and miR-146a was discovered to be one of the miRNAs
induced by LPS in a human monocytic cell line. The induction
of miR-146a was shown to be NF-κB–dependent, and upon
induction, miR-146a functioned to directly down-regulate TNF
receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated
kinase 1 (IRAK1), two of the signal transducers in the NF-κB
activation pathway (9). Based on this study and others (10, 11), we
hypothesized that miR-146a, by repressing TRAF6 and IRAK1,
may have an effect on NF-κB activation, dampening or termi-
nating an inﬂammatory response via a negative-feedback loop. To
deﬁnitively characterize the function of miR-146a in vivo and
directly test the hypothesis that miR-146a is a negative regulator
of the NF-κB pathway, we generated two independent mouse
strains with a targeted germ-line deletion of miR-146a, one on the
mixed C57BL/6 × 129/sv background and one on the pure C57BL/
6 background. Initial study done primarily with the mixed back-
ground miR-146a−/− mice showed that miR-146a−/− mice were
hypersensitive to LPS challenge, and aging miR-146a−/− mice
developed autoimmune-like disease, myeloid proliferation in
their spleens, and hematopoietic tumors (12). However, the cel-
lular lineage of the tumors and the mechanistic basis of miR-
146a–deﬁciency mediated myeloproliferation remained impor-
tant unanswered questions. In addition, the relationship of the
tumor phenotype in miR-146a−/− mice and NF-κB dysregulation
was uncertain because of the multiple potential targets of miR-
146a in different molecular pathways. Here, we focus on char-
acterizing the incidence, cellular lineage, and transplantability of
the tumors, and to understand the molecular basis of oncogenesis.
We have found that when they are allowed to age naturally,
miR-146a−/− mice on a pure C57BL/6 background develop a
chronic inﬂammatory phenotype with progressive myeloprolif-
eration involving both the spleen and the bone marrow, which
eventually progresses to splenic myeloid sarcoma and bone
marrow failure at about 18 mo of age. Lymphomas of either a
B-cell lineage or a mixed T- and B-cell lineage are also observed
in older miR-146a−/− mice at a much higher frequency than in
wild-type animals. Myeloproliferation in miR-146a–deﬁcient mice
are driven primarily by the action of NF-κB because reduction in
the NF-κB level by deletion of the NF-κB subunit p50 effectively
suppresses the pathology. Thus, we have provided genetic evi-
dence that miR-146a functions as a tumor suppressor in both
myeloid and lymphoid cells and that chronic NF-κB activation as
a result of miR-146a–deﬁciency is responsible for driving the
myeloproliferative disease, which can progress to malignant mye-
loid sarcoma.
Results
miR-146a Knockout Mice Develop Myeloid and Lymphoid Malig-
nancies. The miR-146a–deﬁcient pure C57BL/6 mouse was made
by deleting about 300 base pairs of genomic DNA fragment
containing the miR-146a precursor (12). The miR-146a–deﬁcient
mice (homozygous knockouts, designated as miR-146a KO) were
born at the expected Mendelian frequency and appeared to be
normal at birth. However, starting at about 5 to 6 mo of age, they
developed progressively enlarged spleens. By 18 to 22 mo of age,
80% of the KO mice were moribund and were culled for analysis.
However, the entire cohort of age-matched littermate C57BL/6
(WT) control mice, except for one case of thymoma and one case
of seizure, were still alive and healthy (Fig. S1A). On necropsy,
KO mice demonstrated various degrees of splenomegaly, with KO
spleens on average weighing six to seven times more than wild-
type spleens (Fig. S1 B and C). By FACS analysis, splenomegaly
was correlated with a massive expansion of the CD11b+ myeloid
population (Fig. S1 D–F). Expanded splenic hematopoiesis was
also noted based on the increased Ter119+ erythroid precursor
population in the spleen. About 40% of the mice demonstrated
distinct splenic tumors (Fig. 1 A and B). The majority of these
tumors displayed the histologic appearance of a myeloid sarcoma
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(Fig. 1B) (13). FACS analysis of carefully dissected tumors
showed that the cells derived from these tumors expressed the
pan-myeloid antigen, CD11b (Fig. 1B). Occasionally, liver and
kidney were also heavily inﬁltrated by myeloid sarcoma (Fig. S2
A and B). A general role of miR-146a as a tumor-suppressor
miRNA in the hematolymphoid system was demonstrated by the
development of lymphomas of a B-cell or a mixed T- and B-cell
lineage in the cervical lymph node, gastrointestinal tract, liver, and
kidney in about 20% of the KO mice (Fig. 1A). Similar lymphoid
tumors were not identiﬁed in wild-type mice. The lineage of these
tumors was conﬁrmed by FACS as well as immunohistochem-
ical stains (Fig. 1 C and D and Fig. S2 C and D). Histological
analysis revealed that the lymphomas ranged from low-grade
follicular lymphoma (Fig. S2C) to high-grade diffuse large B-
cell lymphoma with apoptotic bodies and atypical mitosis (Fig.
1C and Fig. S2D).
Myeloid Tumors Are Transplantable into Immunocompromised Recipi-
ent Mice. The ability of a mass of cells to form tumors upon
transplantation to a secondary mouse can distinguish a malignant
growth from a reactive inﬂammatory process. KO splenic tumor
cells dissected from the tumor nodules in the spleen and wild-
type control spleen cells were transplanted into immunocom-
promised Rag2−/−γC−/− BALB/c recipient mice intravenously,
with or without transduction by a retrovirus expressing enhanced
GFP and luciferase protein. For experiments with retroviral
transduction, bioluminescent imaging was used as a sensitive
method to track luciferase expression by the transplanted cells in
vivo in recipient mice. Starting 1 to 2 wk after intravenous in-
jection, KO splenocytes showed markedly increased proliferation
compared with wild-type splenocytes in recipient mice (Fig. 2A).
When whole-body bioluminiscence intensity was quantiﬁed over
the course of 8 wk, mice receiving KO splenocytes showed a
progressive increase in signal, culminating in an ∼10- to 20-fold
higher signal, indicating a proliferation of the transplanted cells,
but wild-type cells did not (Fig. 2B). Interestingly, recipient
spleens, kidneys, and livers showed the strongest biolumniscence
signal, indicating the proclivity of transplanted splenic tumor
cells to localize to the same organs where the most signiﬁcant
myeloid tumor pathology was observed in the original KO mice.
By 2 mo following transplantation, most KO recipient mice
became cachectic and moribund, and wild-type recipient mice
showed some mild weight loss. In mice receiving KO spleen cells,
but not in those receiving wild-type spleen cells, necropsy re-
vealed signiﬁcant myeloid pathologies, including enlarged spleens
and massive inﬁltration of kidneys and livers by neoplastic my-
eloid cells (Fig. 2 C–E). Interestingly, not every KO spleen
was transplantable. Transplantation of age-matched KO sple-
nocytes from mice without overt myeloid sarcoma did not result
in signiﬁcant myeloid pathology in recipient mice, suggesting
there is a qualitative difference (e.g., additional mutations) be-
tween KO spleens with myeloproliferation and those with overt
myeloid sarcoma.
Chronic Myeloproliferation and Myeloﬁbrosis in miR-146a–Deﬁcient
Bone Marrow. In addition to splenic myeloproliferation and
myeloid sarcoma, the bone marrow of miR-146a KO mice
showed signiﬁcant myeloproliferative disease. By 18 to 22 mo of
age, the CD11b+ population accounted for 80% of all nucleated
bone marrow cells, and the percentages of CD19+ B cells
dropped to below 10% in miR-146a KO mice (Fig. 3 A and B).
In line with the myeloid-dominated bone marrow, peripheral
blood showed signiﬁcant lymphopenia, anemia, and thrombocy-
topenia, but preserved granulocyte numbers (Fig. 3C and Fig. S3A).
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Fig. 1. miR-146a–deﬁcient mice develop
myeloid and lymphoid malignancies. Mice
were 18- to 22-mo-old miR-146a−/− mice
(KO) and sex- and age-matched C57BL/6
control mice (WT). (A) Incidences of mye-
loid and lymphoid malignancies observed
in wild-type (n = 39) and KO (n = 43) mice.
(B) Photograph, FACS plot, and histologi-
cal analysis of a representative myeloid
tumor from a KO spleen. Panels 3 and 4
show an H&E-stained spleen section. [Scale
bars, (Left) 100 μm; (Right) 40 μm.] Arrows,
mitotic ﬁgures. (C) Photograph, FACS plot,
and histological analysis of a representative
B-cell lymphoma from a KO gastrointestinal
tract. Panels 3 and 5 show an H&E-stained
tumor section; panel 4 shows positive im-
munohistochemical staining for B220 [Scale
bars, (Left to Right) 100 μm in panels 3 and
4 and 40 μm in panel 5.] (D) Photograph,
FACS plot, and histological analysis of
a representative mixed T- and B-cell lym-
phoma from a KO liver. Panels 3–5 show
H&E-stained liver sections. Lym, Lymphoma;
Liv, relatively uninvolved liver. [Scale bars
(Left to Right) are 400 μm, 100 μm, and
40 μm.]
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In addition, the expanded CD11b+ population in both bone
marrow and spleen was also predominantly Gr1+. An increased
expression of macrophage colony stimulating factor receptor
(CSF1R) was also noted in the myeloid population in both
spleen and peripheral blood (Fig. S3B). By 18 to 22 mo of age,
wild-type bone marrow showed partial replacement of bone
marrow cells by adipose tissue as a result of aging, but KO bone
marrow showed end-stage ﬁbrosis or a hypercellular bone mar-
row. The end-stage KO bone marrow was markedly pale by
gross analysis, and histologic sections demonstrated paucicel-
lular marrow with thickened bone and ﬁbrosis (Fig. 3D and Fig.
S3C). This chronic myeloproliferation resembles in some ways
human myeloproliferative diseases that result in an end stage of
marrow ﬁbrosis.
Spleen and Bone Marrow Cells from miR-146a–Deﬁcient Mice Show
Increased Activation of NF-κB–Mediated Transcription. We and
others have previously identiﬁed TRAF6 and IRAK1 as targets
of miR-146a in various cell types, including monocytes and
macrophages (9, 11). Because TRAF6 and IRAK1 are signal
transducers upstream of NF-κB activation, their derepression in
miR-146a–deﬁcient mice could result in increased activation of
NF-κB. In fact, we have recently demonstrated that TRAF6 and
IRAK1 are derepressed in miR-146a KO mice (12). Therefore,
we investigated whether increased NF-κB activation might be
a feature of the myeloproliferation or myeloid sarcoma in the
miR-146a–deﬁcient mice. We extracted RNA from total nucle-
ated spleen cells and total nucleated bone marrow cells and
examined RNA expression levels for some genes well known
to be NF-κB–responsive, including IL-6, TNF-α, monocyte-
chemotatic protein 1 (Mcp1), A20, and the NF-κB subunit p50
(Nfkb1). In the absence of ex vivo stimulation, KO splenocytes
and bone marrow cells showed basally up-regulated expression of
a subset of NF-κB–responsive genes compared with the wild-type
control, suggesting the presence of constitutively activated NF-
κB (Fig. 4 A and B). For some of the genes, such as TNF-α and
Mcp1, the expression was even higher in tumor cells isolated
from the KO spleen (Fig. 4A). To exclude the possibility that
a different cellular composition is responsible for the difference,
especially in spleens where KO spleens showed a threefold in-
crease in CD11b+ myeloid population, we puriﬁed the CD11b+
population from wild-type and KO spleens by magnetic bead-
labeled cell separation (MACS). When the enriched CD11b+
splenocyte population was subjected to the same gene-expression
analysis, NF-κB–activated genes, including TNF-α and Mcp1,
were still up-regulated in the KO population compared with the
wild-type control (Fig. 4C). To further conﬁrm the status of NF-
κB activation, we assessed the level of nuclear translocation of
the NF-κB subunit, RelA (p65), by Western blot analysis of the
nuclear protein extract from total nucleated splenocytes. KO
splenocytes showed a 1.5- to 2-fold higher level of nuclear p65
than wild-type splenocytes, conﬁrming the activated status of
NF-κB (Fig. 4D). It is important to note that not every KO
spleen showed constitutively higher level of nuclear p65 protein.
Increased nuclear p65 correlated well with the presence of my-
eloid sarcoma (Fig. S4), suggesting that the activation of the
NF-κB becomes constitutive only when the KO spleen progresses
from myeloproliferation to myeloid sarcoma.
Reduction in the NF-κB Level Rescues the Myeloproliferation in
Spleen and Bone Marrow. Both gene expression and nuclear pro-
tein analysis indicated that the KO spleen and bone marrow cells
showed increased NF-κB activation. To investigate whether ac-
tivated NF-κB is a causal factor in the observed myeloprolifer-
ation, we bred the miR-146a KO strain with an Nfkb1 (p50) KO
strain to generate the double transgenic strain with homozygous
deletion in both miR-146a and the p50 subunit. p50−/− mice
show no developmental abnormality in the immune system and
elsewhere but display defective B-cell proliferation and speciﬁc
antibody production. Cytokine production, including IL-6, TNF-
α, and IL-1α, from LPS-stimulated macrophage is also impaired
(14, 15). When we intercrossed double heterozygotes for the two
KO genes, the various genotypes were born at the expected
Mendelian frequency (Fig. S5A) and showed no overt abnormal-
ities. Littermates from different genotype groups, miR-146a+/+
p50+/+ (WT), miR-146a−/− p50+/+ (miRKO), miR-146a−/−
p50+/− (miRKO p50HET), and miR-146a−/− p50−/− (DKO),
were aged to 6 to 7 mo and then were killed for analysis for the
development of myeloproliferation in spleen and bone marrow.
As expected, by 6 to 7 mo of age, miR-146a KO mice started to
develop splenomegaly and myeloproliferation. Importantly,
splenomegaly and myeloproliferative disease were signiﬁcantly
reduced in the miR-146a−/− p50+/− group, with the exception of
a few outliers. The rescue from the myeloproliferative phenotype
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Fig. 2. Myeloid sarcoma is transplantable into immunocompromisedRag2−/−γC−/− recipientmice, causing lethalmyeloidpathology.WTdesignatesRag2−/−γC−/−
mice transplanted with wild-type splenocytes; KO designates Rag2−/−γC−/− mice transplanted with miR-146a KO splenocytes (n = 4 for wild-type and n = 4 for
KO; data are representative of three independent experiments). (A) Representative bioluminiscence images of Rag2−/−γC−/− recipient mice splenic side view.
(B) Quantiﬁcation of whole-body bioluminiscence intensity from splenic side view of one representative experiment. Vertical axis is in logarithmic scale.
Transduction efﬁciency is determined by ﬂow cytometric analysis of GFP+ cells before injection. The bioluminescence intensity is normalized to the percentage
of initially transduced cells. (C) Spleen weight of Rag2−/−γC−/− recipient mice (Student t test, *P < 0.05). (D) Photographs of spleens, kidneys, and livers from
representative Rag2−/−γC−/− recipient mice. (E) Flow cytometric analysis of myeloid cells (deﬁned as CD11b+) in representative recipient kidneys and livers. SSC,
side scatter.
9186 | www.pnas.org/cgi/doi/10.1073/pnas.1105398108 Zhao et al.
was more consistent in the miR-146a−/− p50−/− double knockout
(DKO) group, as indicated by the reduction in spleen weight and
the lack of myeloid cell expansion in the spleen and bone marrow
(Fig. 5). In contrast to the pale, ﬁbrotic bone marrow observed in
miRKO femurs, the bone marrow in DKO mice was a vibrant
red color, similar to what was observed routinely in wild-type
mice (Fig. S5B). In the spleens of DKO mice, there was also
signiﬁcant reduction in Ter119+ cells relative to miRKO mice,
suggesting that expanded splenic hematopoiesis was also rescued
by the deletion of p50 in DKO mice (Fig. 5B). We conclude that
activated NF-κB as a result of miR-146a deletion is the primary
factor driving myeloproliferation in miR-146a–deﬁcient mice,
because reduction in the NF-κB level by deleting the NF-κB
subunit p50 effectively rescues the myeloproliferative phenotype.
Discussion
These results and our previous article (12) demonstrate that miR-
146a plays an important role as a tumor suppressor miRNA in he-
matopoietic lineages because chronic miR-146a–deﬁciency in mice
leads to myeloid sarcomas in spleens and lymphomas in various
organs. miR-146a controls myeloproliferation in both the spleen
and bone marrow compartments primarily through negatively
regulating NF-κB. NF-κB is known to activate many genes in-
volved in inﬂammation so that this study provides direct evidence
correlating the chronic inﬂammation caused by activated NF-κB
and the development of progressive myeloproliferative disease.
Consistent with the initial observation of miR-146a KO mice
on the mixed C57BL/6 × 129/sv genetic background (12), miR-
146a KO mice on the pure C57BL/6 background developed
progressive myeloproliferation in their spleens, although the
onset was delayed compared with the mixed background mice.
miR-146a KO on the pure C57BL/6 background also developed
signiﬁcant myeloproliferative disease in the bone marrow, which
was not observed in the mixed background strain. Moreover,
miR-146a KO mice on the pure C57BL/6 background displayed
less severe autoimmune-like disease but developed a higher in-
cidence of tumor later in life. All these data indicate that the
genetic background can signiﬁcantly inﬂuence the phenotypic
manifestation of deleting the miR-146a KO gene.
It is interesting that miR-146a–deﬁcient mice showed no ob-
vious abnormality early on when left unchallenged but gradually
developed myeloproliferation in both spleen and bone marrow
compartments, starting at about 5 to 6 mo of age. Eventually,
more than 50% of the mice developed myeloid sarcomas and
lymphomas at about 18 to 22 mo of age. miR-146a normally
down-regulates TRAF6 and IRAK1, and in the miR-146a–
deﬁcient mice, derepression of these important signal trans-
ducers may increase signaling to the NF-κB pathway. It should
be noted that overexpression of TRAF6 or IRAK1 in the 293
human embryonic kidney cell line is able to activate NF-κB (16,
17), suggesting a possibility of cell-intrinsic activation of NF-κB
when TRAF6 or IRAK1 is overexpressed at a high level. How-
ever, this is unlikely to be the case in miR-146a KO mice. We
believe that the NF-κB activation in miR-146a KO mice likely
involves external stimulation from other cells (autoimmune
stimuli) or from environmental pathogens/commensal bacteria
for TRAF6/IRAK1 to amplify the signal, and that the mecha-
nism of myeloproliferation and oncogenesis requires repeated
episodes of activation of NF-κB from external stimulation. In
support of this notion, our previous article reports an increased
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Fig. 3. Chronic myeloproliferation and myeloﬁbrosis occur in miR-146a–
deﬁcient bone marrow. Mice were 18- to 22-mo-old miR-146a−/− mice (KO)
and sex- and age-matched wild-type control mice (WT). Data are shown as
Mean ± SEM. Each individual dot represents one individual mouse. (A) Flow
cytometric analysis of nucleated bone marrow cells from one representative
wild-type mouse and one representative KO mouse for B cells (deﬁned as
CD19+) and myeloid cells (deﬁned as CD11b+). (B) Percentage of B cells
(deﬁned as CD19+) and myeloid cells (deﬁned as CD11b+) in nucleated bone
marrow cells by ﬂow cytometric analysis (n = 12 for WT and n = 17 for KO
from at least three independent experiments). (C) Absolute numbers of total
white blood cells, lymphocytes, red blood cells, and platelets by complete
blood count analysis (n = 8 for WT and n = 8 for KO). (D) Representative H&E-
stained tibia sections from KO mice showing myeloﬁbrosis and wild-type
control. WT, wild-type bone marrow; adi, adipose tissue. KO1, markedly
hypercellular KO bone marrow that contains virtually no megakaryocytres
(arrowhead, Lower Left) or erythroid islands (outlined by dashed line, Lower
Left). KO2: ﬁbrotic KO bone marrow; arrows in the Upper Right, a broad
band of ﬁbrosis, of which there are many in this ﬁeld; within the dotted line,
an area of new bone formation that may represent end-stage ﬁbrosis;
(Lower Right) the interface between an area of ﬁbrosis (ﬁb) with entrapped
myeloid cells and new bone formation (bone). [Scale bars, (Upper) 200
microns; (Lower) 40 μm.]
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expression of both TRAF6 and IRAK1 at the protein level in
bone marrow-derived macrophages from young miR-146a KO
mice. However, there was no difference in the serum levels of
TNF-α and IL-6 inﬂammatory cytokine between young wild-type
and KO mice without LPS challenge (12). In addition, consti-
tutive NF-κB activity detected by conventional biochemical
methods was only consistently noted in spleens with overt myeloid
sarcoma (Fig. S4). Based on this evidence, we suggest that the
activation of the NF-κB may only become constitutive and sig-
niﬁcant when KO spleens transition from the premalignant my-
eloproliferative state to malignant myeloid tumor. Given the
long latency and the partial penetrance of the tumor phenotype,
there are likely secondary mutations cooperating in the onco-
genesis, either complementing the NF-κB activity or amplifying
it, resulting in malignant tumors. It will be interesting to iden-
tify secondary mutations driving this progression and malignant
transformation.
NF-κB family transcription factors are homo- or heterodimers
of ﬁve subunits, RelA (p65), Nfkb1 (p50), Nfkb2 (p52), RelB,
and c-Rel. Among these subunits, p65 and p50 are thought to
play an important role in the induction of many of the in-
ﬂammatory genes (18). In addition, nfkb1ΔCT/ΔCT mice, with el-
evated p50 activity as a result of targeted deletion of the
C-terminal ankyrin repeats, display phenotypes similar to those
of miR-146a−/− mice, namely chronic inﬂammation with spleno-
megaly and enlarged lymph nodes (19). Moreover, deletion of
p50 is able to partially rescue IkBα-deﬁcienct mice, which display
constitutive NF-κB activation, increased granulopoiesis, and neo-
natal lethality (20). Given the importance of the p50 subunit to
NF-κB–driven inﬂammation, we bred miR-146a−/− mice with
p50−/− mice to investigate the role of NF-κB activation in the
pathogenesis of myeloproliferation in miR-146a-deﬁcient mice.
We showed that p50-deﬁciency effectively rescued myeloprolif-
eration in miR-146a–deﬁcient mice. The rescue seen in miRKO
p50HET mice was not consistent and complete, but merely a
delay of symptoms, because by about 1 y old, mice in the miRKO
p50HET group started to show increased myeloid cells but the
DKO mice continued to show consistent rescue of the myelo-
proliferative phenotype. The 50% increase in spleen weight and
the marginal increase in CD11b+ and Ter119+ cells in the spleen
of DKO mice, compared with wild-type (Fig. 5 B and C), suggest
that the other pathways and factors other than p50 may also be
involved. In addition, p50 deﬁciency may not rescue all of the
phenotypes in miR-146a KO mice, such as autoimmunity as a
result of defective regulatory T cells and activated effector T
cells, which has been shown to be caused by a different path-
way, the STAT1/IFN pathway (21). Autoimmune inﬂammation
may contribute to the modestly increased spleen weight in the
DKO mice.
Constitutive NF-κB activation is a well-recognized phenome-
non in lymphoid and plasma cell malignancies, but the status of
NF-κB activation in myeloid malignancies is less well charac-
terized. Some recent studies have demonstrated constitutive
NF-κB activity in cells from high-risk myelodisplastic syndrome,
some acute myeloid leukemia cases, and chronic myelogenous
leukemia with blast crisis, suggesting that constitutive NF-κB
activation may be associated with more advanced myeloid ma-
lignancies (6, 22, 23). In many of these cases, the mechanisms
for constitutive NF-κB activation remain to be established. It is
likely that some of these myeloid malignancies with intrinsic
NF-κB activity may have down-regulated miR-146a expression.
Indeed, reduced miR-146a has been found in myelodisplastic
syndrome with chromosome 5q deletion and a subset of acute
myeloid leukemia cases (24, 25).
Based on this work and the work of others, it seems apparent
that miR-146a is an important component of immune-cell gene
regulation and that its main function is to negatively regulate
NF-κB. We demonstrate pathologic states as a consequence of
miR-146a deﬁciency, corroborating work from other groups
showing deregulation of this miRNA in human diseases. Further
work is required to better understand the pathogenesis of miR-
146a–deﬁcient diseases in humans and to develop methods to
deliver miR-146a to immune cells to reduce NF-κB activation.
Materials and Methods
Mice. For a description of the miR-146a−/− generation and genotyping, see SI
Materials and Methods and ref. 12. All experiments with miR-146a−/− and
p50−/− (15) mice were approved by the Institutional Animal Care and Use
Committee of the California Institute of Technology.
Survival and Tumor Incidence Study. Survival and tumor incidence studies
were done by following a cohort of about 40 miR-146a−/− and 40 littermate
wild-type control mice for up to 24 mo. Mice were carefully monitored for
the development of diseases and were killed when visibly ill. Tumor di-
A
B
C
D
Fig. 4. Spleen and bone marrow cells from miR-146a–deﬁcient mice (KO)
show increased activation of the NF-κB–mediated transcription. Mice were
18- to 22-mo-old miR-146a−/−mice (KO) and sex- and age-matched wild-type
control mice (WT). Data are shown as mean ± SEM. n represents the number
of mice analyzed from at least two independent experiments. Student t test,
*P < 0.05, ***P < 0.005. (A) Gene-expression analysis of NF-κB–responsive
genes in wild-type (n = 7) nucleated splenocytes, KO (n = 13) nucleated
splenocytes, and myeloid tumor cells (Tumor, n = 7) isolated from KO spleen
by gross dissection. (B) Gene-expression analysis of NF-κB–responsive genes
in wild-type (n = 9) and KO (n = 11) bone marrow cells. (C) Gene-expression
analysis of NF-κB–responsive genes in CD11b+ population puriﬁed with
MACS beads (WT n = 9 and KO n = 6). (D) Western blot analysis of the nuclear
protein extracts from wild-type or KO spleen. Data are representative of
three independent experiments.
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agnosis was based on a combination of gross examination, histological
analysis, immunohistochemistry, and ﬂow cytometric analysis.
Tumor Transplantation Experiments. Tumor was grossly dissected from miR-
146a−/− mice. Splenic tumor cells (1 × 106) or an equal number of wild-type
splenocytes were injected into 8- to 12-wk-old Rag2−/−γC−/− recipients via
retro-orbital vein. For experiments with retro-viral transduction, MIG-Luc
(MSCV-IRES-GFP vector expressing ﬁreﬂy luciferase) retroviruses were pre-
pared and used to infect murine cells as previously described (26). Flow
cytometry was used to quantify the percentage of infected cells (GFP+) be-
fore injection and bioluminescence imaging (Xenogen) was used to monitor
in vivo cell growth in Rag2−/−γC−/− recipients weekly for up to 2 mo. Bio-
luminescence intensity was quantiﬁed with Living Image 2.50.1 (Xenogen).
Expanded methods are found in SI Materials and Methods.
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Fig. 5. Reduction in the NF-κB level by deleting the p50 subunit of NF-κB effectively rescues the myeloproliferative phenotype in miR-146a–deﬁcient mice. All
mice were 6- to 7-mo-old miR-146a+/+, p50+/+ (WT), miR-146a−/−, p50+/+ (miRKO), miR-146a−/−, p50+/− (miRKO p50HET), or miR-146a−/−, p50−/− (DKO) mice (n =
17 for WT, n = 24 miRKO, n = 10 for miRKO p50HET, and n = 9 for DKO). Data are shown as mean ± SEM from at least three independent experiments. Student
t test, *P < 0.05, **P < 0.01, and ***P < 0.005. (A) Spleen weight of wild-type, miRKO, miRKO p50HET, and DKO mice. (B) Percentage of T cells (deﬁned as
CD3ε+), B cells (deﬁned as CD19+), myeloid cells (deﬁned as CD11b+), and erythroid cells (deﬁned as Ter119+) in nucleated spleen and bone marrow cells from
wild-type, miRKO, miRKO p50HET, and DKO mice by ﬂow cytometric analysis.
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